Key facts
- LUCAI Bio’s last known valuation is $2.0M (May 2025).
- Notable investors include VX Ventures.
- Status: Privately Held (backing).
Investors
1- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for LUCAI Bio
- ·The full record, as it builds
Funding rounds
No funding rounds for LUCAI Bio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About LUCAI Bio
Developer of AI-powered bioinformatics platforms designed to accelerate research and development in biotechnology sectors such as healthcare, agriculture, energy, and food. The company addresses the challenge of integrating artificial intelligence into biological research by offering tailored bioinformatics services that enable teams to run predictions, validate hypotheses, and make confident decisions within their R&D workflows, enhancing the speed, precision, and scalability of scientific innovation
- Sector
- Healthcare
- HQ
- Argentina
- Founded
- 2025
- Employees
- 10
- Website
- lucai.bio/
- Ownership
- Privately Held (backing)
LUCAI Bio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in LUCAI Bio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on LUCAI Bio in its N-PORT filings yet. We sweep new filings monthly.